The six-monthly injectable is expected to significantly strengthen efforts to reduce new HIV infections. Image: Supplied
Health
1Min
South Africa
The Health Department says the arrival of Lenacapavir injections marks a major step forward in reducing new HIV infections, especially among high-risk groups.
South Africa has received its first batch of the HIV prevention medicine Lenacapavir, with 37,920 doses now in the country, the Department of Health confirmed on Tuesday.
The department said the six-monthly injectable is expected to significantly strengthen efforts to reduce new HIV infections and help end AIDS as a public health threat by 2030, in line with the global strategy for 2026 to 2030.
According to the department, Lenacapavir forms part of integrated, people-centred HIV prevention services and offers new hope for individuals who face challenges accessing or adhering to existing prevention methods.
“This six-monthly injectable arrived in the country last week Thursday and is expected to expand HIV prevention choices, improving adherence, especially among vulnerable groups such as adolescent girls and young women, sex workers, and men who have sex with men,” the department said.
Health Minister Aaron Motsoaledi welcomed the development, describing it as a major breakthrough in the country’s HIV response.
The department added that an official launch date will be announced in the coming weeks, with a phased rollout plan to be outlined. The launch is expected to be led by President Cyril Ramaphosa.
While Lenacapavir is not a vaccine, it is considered one of the most significant advances in HIV prevention in recent years.
